Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Charpentier C, et al. Among authors: tubiana r. Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28. Antimicrob Agents Chemother. 2011. PMID: 21189351 Free PMC article.
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.
Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F, Costagliola D. Katlama C, et al. Among authors: tubiana r. Ann Intern Med. 1998 Oct 1;129(7):525-31. doi: 10.7326/0003-4819-129-7-199810010-00003. Ann Intern Med. 1998. PMID: 9758571
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.
Ghosn J, De Montgolfier I, Cornélie C, Dominguez S, Pérot C, Peytavin G, Marcelin AG, Pauchard M, Ouagari Z, Bonmarchand M, Agher R, Calvez V, Bricaire F, Dommergues M, Katlama C, Tubiana R. Ghosn J, et al. Among authors: tubiana r. Antimicrob Agents Chemother. 2008 Apr;52(4):1542-4. doi: 10.1128/AAC.01301-07. Epub 2008 Feb 4. Antimicrob Agents Chemother. 2008. PMID: 18250187 Free PMC article. Clinical Trial.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: tubiana r. J Antimicrob Chemother. 2010 Apr;65(4):749-51. doi: 10.1093/jac/dkq029. Epub 2010 Feb 11. J Antimicrob Chemother. 2010. PMID: 20150182
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C. Caby F, et al. Among authors: tubiana r. Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502. Scand J Infect Dis. 2010. PMID: 20222846
402 results